Managing dyslipidaemia: Evolving role of combination therapy

Journal of the Indian Medical Association

Volumn 109, Issue 8, 2011, Pages 549-552

  Bandgar, Tushar R ^a   Faruqui, Arif A ^b  

^a KEM HOSPITAL   (India)

^b NONE

Author keywords

Atorvastatin; Combination therapy; Dyslipidaemia; Ezetimibe; Fenofibrate; Niacin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG INDICATION; DYSLIPIDEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE;

EID: 80052744234     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gupta R, Gupta VP, Sarna M, Bhatnagar S, Thanvi J, Sharma V, et al - Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J 2002; 54: 59-66.
2. American Diabetes Association - Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27: S68-S71.
3. Croom KF, Plosker GL - Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005; 65: 137-52.
4. Christie MB, John H, Alberto N, Lorenzo M, Leslie JL, Ramachandran S, et al - Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-12.
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al - Stone NJ Coordinating Committee of the National Cholesterol Education Program: implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-61.
6. Evans M, Roberts A, Rees A - The future direction of cholesterol- lowering therapy. Curr Opin Lipidol 2002; 13: 663-9.
7. Huff MW - Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis. Can J Clin Pharmacol 2003; 10: 26A-32A.
8. Gagné C, Gaudet D, Bruckert E - Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia: Ezetimibe Study Group. Circulation 2002; 105: 2469-75.
9. Liamis G, Kakafika A, Bairaktari E, Miltiadous G, Tsimihodimos V, Goudevenos J, et al - Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Curr Med Res Opin 2002; 18: 125-8.
10. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al - Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-53.
11. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG - Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-202.
12. Shek A, Ferrill MJ - Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-17.
13. Third Report of the National Cholesterol Education Program (NCEP) - Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
14. Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA - Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy 2005; 25: 345-51.
15. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86:11-41.
16. Morgan J, Carey C, Lincoff A - High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-65.
17. Expert Group on HDL Cholesterol - The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-43.
18. LA - Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol 2006; 21: 336-44.
19. Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA - Comparison of extended release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 2002; 89:1306-8.